DiscoverX Launches Toolbox Products for GPCR β-Arrestin Cell Line and Cell-Based Assay Generation

Release date: 6/28/2016

Announcing PathHunter® β-Arrestin Retroparticles

Fremont, CA – June 28, 2016 – DiscoverX Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, today announced the launch of PathHunter® β-Arrestin Retroparticles products, providing scientists ultimate flexibility to develop stable β-arrestin cell lines and cell-based assays in almost any cell type.
G protein-coupled receptors (GPCRs) steadily remain a critical drug discovery target class due to the many biological processes they initiate and their involvement in multiple diseases such as neurodegeneration, cancer, cardiovascular diseases, and metabolic disorders. DiscoverX’s β-arrestin cell-based assays offer a G-protein independent pathway that is universal and provides alternative opportunities for development of novel drugs.
Novel assays to study β-arrestin recruitment are clearly needed to analyze tissue-specific variations, compare ligand response in different species (orthologs), evaluate specific GPCR mutants that cause disease, or study non-GPCR β -arrestin binding proteins. DiscoverX’s PathHunter β-Arrestin Retroparticles toolbox products provide a solution to these challenges by offering the most flexible option for customers to create their own stable β-arrestin cell lines and cell-based assays for drug discovery.
“DiscoverX is the market leader for GPCR solutions by providing the largest portfolio of validated and optimized GPCR products and services. With the launch of the PathHunter β-Arrestin Retroparticles, our customers now have complete access to our open platform solution that provides them with control to develop their own GPCR β-arrestin cell lines and cell-based assays in almost any cell type of their choice,” stated Todd R. Nelson, Ph.D., CEO of DiscoverX.
PathHunter β-Arrestin Retroparticles provide a potent retroviral vehicle for stable delivery of a β-arrestin construct into almost any dividing cell line, enabling the creation of β-arrestin cell-based assays expressing a target of choice. The easy-to-follow protocol is designed for rapid implementation in any lab without the need for costly assay development. Theresa Schaub, Sr. VP of Commercial Operations for DiscoverX, stated, “Now customers can easily study β-arrestin recruitment investigating tissue specific variations using different cell types, as well as analyze ligand responses to mutant or ortholog GPCRs, or any other β-arrestin binding proteins.”
For more information on DiscoverX’s PathHunter β-Arrestin Retroparticles, visit

About DiscoverX

DiscoverX Corporation, headquartered in Fremont, CA, USA, is a leader in the design, manufacture and sale of biochemical and cell-based assays for the drug discovery & life science markets. This industry-leading portfolio of products and services, under the KINOMEscan®, PathHunter® and BioMAP® brands, are used to aid life science research and enable rapid development of safe and effective biologic and small molecule drugs, by improving research productivity, effectiveness of screening, lead optimization & bioanalytical campaigns, as well as providing predictive tools that deliver physiologically relevant insights on drug molecules from early discovery through pre-clinical development. DiscoverX embodies an innovative approach to creating life science tools that have been widely adopted across the globe in pharmaceutical, biotechnology and academic laboratories.

Media Contact
Theresa Schaub, Sr. VP Global Marketing, DiscoverX